Evidence map›Paper›PMID 24990477›Full record

ArticleBMC infectious diseases2014

An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection.

Haifeng Lu, Chunxia Zhang, Guirong Qian, Xinjun Hu, Hua Zhang, Chunlei Chen, Weifeng Liang, Hainv Gao, Yunmei Yang, Lanjuan Li

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome.International journal of molecular sciences · 2023
    Review
  3. Active immunization withJournal of thoracic disease · 2023
    Article
  4. Article
  5. Review
  6. Precision medicine journey through omics approach.Journal of diabetes and metabolic disorders · 2022
    Review
  7. Roles of the gut microbiota in severe SARS-CoV-2 infection.Cytokine & growth factor reviews · 2022
    Review
  8. Article
  9. Effects of Live CombinedFrontiers in cellular and infection microbiology · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Novel Avian Influenza A Virus Infections of Humans.Infectious disease clinics of North America · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Haifeng Lu
Chunxia Zhang
Guirong Qian
Xinjun Hu
Hua Zhang
Chunlei Chen
Weifeng Liang
Hainv Gao
Yunmei YangState Key Laboratory Diagnosis and Treatment for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China. ymyang@zju.edu.cn.
Lanjuan Li
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSelective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and reducing secondary infections.

methodsComprehensive therapies were dependent on the individual clinical situation of subjects, and were divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage, and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE) were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens.

resultsDifferent antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of communities under the continual suppression of the same antibiotics, and significant changes when new antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail in these patients.

conclusionsElderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration strategies for secondary infection were unsatisfactory in elderly and critically ill patients.

Indexed as

Influenza A Virus, H7N9 SubtypeAgedAnti-Bacterial AgentsAntiviral AgentsBifidobacteriumChinaFemaleHumansImmunotherapyInfluenza, HumanMaleMiddle AgedProbioticsAnti-Bacterial AgentsAntiviral Agents

Identifiers

PMID24990477
PMCPMC4107951
OpenAlexW2059592158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.